Buy or sell Moderna Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Moderna Therapeutics Stock
Moderna Therapeutics specializes in drug discovery and drug development based on messenger RNA.
About Moderna Therapeutics Stock
Moderna Therapeutics develops messenger RNA therapeutics. Itprovides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology.
Investors
Sequoia Capital
Market Kurly, Robinhood, Airbnb, Instacart, Tokopedia, Stripe, DoorDash, Rappi, CoinSwitch Kuber, UiPath
Viking Global Investors
Impossible Foods, Moderna Therapeutics, Apeel Sciences, Adaptive Biotechnologies, Arctic Wolf, Talkdesk, Druva, Color, Clip, Iterable
Wellington Management Company
Magic Leap, Moderna Therapeutics, Compass, Pinterest, Oscar Health, Dataminr, DocuSign, Lookout, Sprinklr, PagerDuty
Funding History
December 2012 | $40.0M |
---|---|
October 2013 | $24.6M |
November 2013 | $110M |
January 2014 | $25.0M |
January 2015 | $450M |
January 2016 | $20.0M |
August 2016 | $474M |
September 2016 | $8.0M |
February 2018 | $500M |
May 2018 | $125M |
Management
Chief Executive Officer
Stéphane Bancel
President
Stephen Hoge
Chief Financial Officer
Lorence Kim
Chief Digital Officer
Marcello Damiani
Chief Human Resources Officer
Annie Drapeau
Chief Sustainability Officer and Chief of Staff
Stephen Harbin
Chief Corporate Affairs Officer
Megan Pace
Chief Medical Officer
Tal Zaks
Press
Wall Streets Journal - Mar, 16 2020
Wall Streets Journal - Mar, 4 2020
In-PharmaTechnologist.com - Jul, 23 2018
Boston Business Journal - Jul, 17 2018
Business Wire (press release) - Jul, 17 2018
Business Wire (press release) - Jul, 11 2018
Xconomy - May, 9 2018
Forbes - May, 3 2018
Genetic Engineering & Biotechnology News - Feb, 2 2018
- Dec, 9 2016
- Oct, 28 2016
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase